[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-low-back-pain-clbp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-low-back-pain-clbp":68},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,54,0,25,[9,53,84,107,134,162,188,212,247,275,304,326,346,378,405,434,460,487,517,541,565,592,622,646,671],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100652389","virtual-tai-chi-for-chronic-low-back-pain-spine-2027-100652389",false,"NCT07772154","Virtual Tai Chi for Chronic Low Back Pain (Spine 2027)","A Pragmatic Randomized Controlled Trial of Virtual Tai Chi for Chronic Low Back Pain: Effects on Disability, Pain, Quality of Life, and Healthcare Costs","Inclusion Criteria:\n\n* Age 18 years or older\n* Current non-specific low back pain lasting 12 weeks or more, with average pain over the past 7 days rated 4 or higher on a 0 to 10 scale\n* Understands written and spoken English\n* Has consistent internet access and is able to participate in virtual sessions\n* Agrees to appear on video during tai chi sessions, visible to the instructor and other participants\n* Willing to participate in a 12-month study including a 3-month foundation training phase with two 60-minute virtual live tai chi classes per week, 10 minutes of daily home practice, monthly 60-minute booster sessions during months 4 through 12, and five online surveys over 12 months at months 0, 2, 3, 6, and 12\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Currently pregnant\n* Regular tai chi or qigong practice or research study participation in the past 5 years\n* History of spine surgery within the past 6 months\n* Severe psychiatric or medical comorbidities that, in the principal investigator's judgment, would make participation unsafe or not feasible\n\nNote on the second exclusion bullet: the protocol wording leaves open whether \"research study participation\" means participation in any research study or only in tai chi or qigong research. That wording has been carried over exactly as approved rather than clarified here, because the registry record should match the protocol. If the ambiguity is worth resolving, it belongs in a future amendment and then in a record update, not in this response.","ALL","18 Years",{"count":20,"type":21},600,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study tests whether a virtually delivered integrated tai chi, qigong, and meditation program, added to usual care, improves chronic low back pain, disability, quality of life, and healthcare costs compared with usual care alone. Adults with chronic low back pain are randomized to begin the program immediately (Tai Chi Now) or after a six-month period (Tai Chi Later). Outcomes are collected by online survey over twelve months.",[27,28],"Low Back Pain","Chronic Low-back Pain (cLBP)",[30,31,32,33,34,35,36,37,38,39],"tai chi","qigong","meditation","mind-body","virtual care","telehealth","disability","quality of life","cost-effectiveness","non-pharmacologic","NOT_YET_RECRUITING","2026-08-17",{"date":43,"type":44},"2026-08-19","ACTUAL",{"date":46,"type":21},"2026-10-01",{"date":48,"type":21},"2028-02-15",{"name":50,"class":51},"New York Medical College","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":77,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100631188","neuroimmune-responses-to-exercise-in-chronic-back-pain-100631188","NCT07497425","Neuroimmune Responses to Exercise in Chronic Back Pain","Neuroimmune Responses to Physical Exercise Training in Chronic Primary Low Back Pain","eCLBP","Inclusion Criteria-CLBP patients:\n\n* Have a diagnosis of chronic primary LBP, according to the criteria established by NIH Task Force on Research Standards for CLBP (Deyo et al., 2015). This will be determined by 1) the response to the National Institutes of Health minimum dataset for CLBP (NIH-md), including that LBP has been persistent for at least 3 months or recurrent for at least half of the days in the past 6 months, and 2) the results of a complete case history and physical examination (including functional tasks, quantitative sensory testing, and, if needed, neuro-orthopedic, palpation and range of motion assessments);\n* Report a CLBP intensity of at least 4 in a 0-10 numerical rating scale (0 = no pain, 10 = maximum possible pain).\n\nInclusion Criteria-Healthy controls:\n\n\\- Be over 18 years and under 75 years of age;\n\nExclusion Criteria-CLBP patients:\n\n* Present any red flags indicative of serious pathology comorbid or as the cause of CLBP (Finucane et al., 2020);\n* Have a CLBP phenotype characterized by predominant nociceptive (as in fracture, infection, malignancy, inflammatory or rheumatic spondyloarthropathy, cauda equina syndrome, confirmed by MRI when suspected) or neuropathic pain mechanisms, the latter assessed through score in the DN4 questionnaire (Nijs, et al., 2024);\n* Present chronic or acute pain of higher intensity or perceived disability in any other body site than the low back;\n* Medical history of diabetes, neurological or psychiatric disorder;\n* Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);\n* Following a regular structured PE training program (\\>60 min\u002Fweek) at study's onset, and;\n* Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).\n\nExclusion criteria-Healthy controls:\n\n* Have symptoms or a diagnosis of any acute or chronic pain conditions;\n* Medical history of diabetes, neurological or psychiatric disorder;\n* Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);\n* Following a regular structured PE training program (\\>60 min\u002Fweek) at study's onset, and;\n* Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).",true,"75 Years",{"count":64,"type":21},216,[24],"The goal of this mechanistic clinical trial is to learn how physical exercise affects the body and brain in people with chronic low back pain. The study will examine whether a 12-week online exercise program changes these measures compared with a waitlist group. Researchers will also study immune activity and brain function in people with chronic low back pain and compare them with healthy participants. Participants will complete questionnaires, provide blood samples, and undergo brain imaging scans.",[68],"Chronic Low Back Pain (CLBP)",[70,71,72,73,74,75],"mechanisms","immune system","inflammation","brain","chronic pain","exercise","RECRUITING",{"date":43,"type":44},{"date":79,"type":44},"2025-06-01",{"date":81,"type":21},"2029-06-30",{"name":83,"class":51},"McGill University",{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":52},"100616496","phase-2-psilocybin-assisted-physical-therapy-in-chronic-low-back-pain-100616496","NCT07306364","Psilocybin-Assisted Physical Therapy in Chronic Low Back Pain","Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes","Inclusion Criteria:\n\n* 1\\. Ability to provide informed consent in English.\n* 2\\. Provision of signed and dated informed consent form.\n* 3\\. Stated willingness to comply with all study procedures and availability for the duration of the study.\n* 4\\. Male and female participants aged 18-65 years.\n* 5\\. CLBP, uniformly defined as high-impact or bothersome non-cancer low back pain lasting ≥ three months that occurs most days and limits life or work activities.\n* 6\\. At least moderate pain-related disability as measured by a total score on the ODI ≥ 15.\n* 7\\. For women of childbearing potential, must have a negative urine pregnancy test at screening and immediately before dose administration.\n\n  * Negative urine pregnancy test at screening and immediately before dose administration.\n  * Use of one highly effective contraception (e.g., IUD, barrier method) for ≥ 1 month prior to screening.\n* 8\\. Participants are required to commit to employing dual contraceptive methods throughout the study and to abstain from sperm or egg donation during the study period and for 28 days following the final drug dose for ova, and for 90 days following the final drug dose for sperm. Dual contraceptive methods encompass the use of a barrier contraceptive, such as condoms, coupled with another effective method capable of preventing pregnancy, such as oral or parenteral contraceptives, intrauterine devices, spermicide, and the like.\n* 9\\. Resting blood pressure ≤ 140\u002F90 mmHg (average of three screenings) and resting heart rate 60-100 bpm.\n* 10\\. Normal screening EKG: QTcF \\\u003C 450 ms; no clinically significant arrhythmias, ischemia, or bundle branch block.\n* 11\\. Hepatic and renal function within acceptable limits: AST\u002FALT ≤ 2× ULN; bilirubin ≤ 1.5× ULN; eGFR ≥ 50 mL\u002Fmin\u002F1.73 m².\n* 12\\. Ability to safely ingest oral capsules for the dosing visit.\n* 13\\. Safe transportation plan after the dosing session (e.g., designated driver).\n* 14\\. Signed medical release permitting the study team to communicate with outside providers for medication\u002Ftherapy history or crisis management.\n* 15\\. Designation of an adult emergency contact (relative, spouse, close friend) willing to monitor for mood\u002Fbehavior changes post-dose and provide transportation if needed.\n* 16\\. Agreement to attend preparatory and integration sessions, follow-up visits, and to respond to telephone\u002Femail contacts.\n\nExclusion Criteria:\n\n* 1\\. Hallucinogen Use Disorder or Hallucinogen Persisting Perceptual Disorder.\n* 2\\. Personal or family history of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder with psychotic features; any history of substance-induced psychosis or current psychotic symptoms at Screening per the Brief Psychiatric Rating Scale.\n* 3\\. Active suicidal ideation or behavior in the past 3 months, as indicated on the C-SSRS.\n* 4\\. Lifetime use of classic psychedelics (5-HT2A agonists) within the preceding 12 months, or unwillingness to abstain from their use for up to 4 weeks post-dose.\n* 5\\. Current moderate or severe depression, as indicated by a score of ≥ 3 on the depression subscale (items 1 and 2) of the Patient Health Questionnaire-4 (PHQ-4).\n* 6\\. Total score on the ODI ≥ 35, indicating an individual is \"completely disabled.\"\n* 7\\. Meeting DSM-5 criteria for alcohol or substance use disorders (other than tobacco use disorder) within the last year; use of THC-containing products \\> 2×\u002Fweek over the past 30 days or unwillingness to abstain for at least 1 week pre-dose through 4 weeks post-dose. Abstinence will be confirmed via point-of-care urine 11-nor-9-carboxy-THC testing with a cut-off ≤ 50 ng\u002FmL.\n* 8\\. Clinically significant medical disorders (e.g., moderate-to-severe hepatic impairment \\[Child-Pugh B\u002FC\\], AST\u002FALT \\> 2× ULN, bilirubin \\> 1.5× ULN, eGFR \\\u003C 50 mL\u002Fmin\u002F1.73 m², diabetes, uncontrolled thyroid disease).\n* 9\\. Neurological conditions altering nociceptive response (e.g., stroke, neuropathy) or history of seizure\u002Fhead injury with \\> 30 minutes loss of consciousness.\n* 10\\. Contraindications to nociceptive testing (e.g., untreated hypertension \\> 140\u002F90 mmHg).\n* 11\\. Current use of serotonergic medications (e.g., SSRIs, SNRIs, TCAs).\n* 12\\. Current regular use of medications affecting pain (e.g., opioids, gabapentinoids, cyclobenzaprine).\n* 13\\. Current regular use of inhibitors of UGT1A9, UGT1A10, MAO and aldehyde or alcohol dehydrogenase.\n* 14\\. Major neurocognitive disorders (e.g., dementia) or any cognitive deficit impairing consent\u002Fparticipation.\n* 15\\. Abnormal EKG findings (e.g., ischemia, infarct patterns, bundle branch block, atrial fibrillation, QTcF ≥ 450 ms).\n* 16\\. Resting QTcF prolongation or other torsades de pointes risk factors (uncontrolled electrolyte disturbances, family history of sudden death, torsadogenic medications).\n* 17\\. Any other condition that, in the investigator's judgment, would compromise safety or ability to complete the study.\n* 18\\. Known or suspected cardiovascular disease, including but not limited to atrial fibrillation, coronary artery disease, history of myocardial infarction, structural heart disease, congestive heart failure, or uncontrolled hypertension.","65 Years",{"count":93,"type":21},45,[95],"PHASE2","The purpose of this research study is to investigate whether a single administration of psilocybin can improve interoceptive awareness (awareness of bodily sensations) in individuals with chronic low back pain undergoing physical therapy, and whether these improvements are linked to pain relief and better physical therapy outcomes.",[68,98,99],"Physical Therapy","Psilocybin",{"date":43,"type":44},{"date":102,"type":21},"2026-10",{"date":104,"type":21},"2029-06",{"name":106,"class":51},"Yale University",{"id":108,"slug":109,"hasResults":12,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":114,"enrollmentInfo":115,"targetDuration":117,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":52},"100651759","pain-phenotypes-in-individuals-with-chronic-low-back-pain-100651759","NCT07766200","Pain Phenotypes in Individuals With Chronic Low Back Pain","Pain Phenotypes in Chronic Low Back Pain Based on IASP Criteria","Inclusion Criteria:\n\n* Low back pain persisting for at least 3 months or present for at least 3 months during the previous 6 months, defined as pain located between the posterior lower costal margins and the inferior gluteal folds\n* Pain intensity ≥2 on the Numeric Rating Scale\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Inability to read and write Turkish\n* History of lumbar surgery\n* Presence of a systemic condition affecting sensory function\n* History of spinal surgery within the previous 6 months or suspected spinal fracture\n* Inability to complete the study assessments","70 Years",{"count":116,"type":21},80,"1 Day","OBSERVATIONAL","This observational cross-sectional study aims to determine pain phenotypes in individuals with chronic low back pain (CLBP). Participants will be classified according to a mechanism-based clinical pain phenotyping algorithm as having nociceptive, neuropathic, nociplastic, or mixed pain. Clinical history, quantitative sensory assessment, pain characteristics and distribution, central sensitization-related symptoms, disability, health-related quality of life, and pain catastrophizing will be assessed. In addition, the intra-rater and inter-rater reliability of the pain phenotyping algorithm will be investigated, and the clinical characteristics of different pain phenotypes will be compared.",[28],[122,123,74,124],"pain phenotype","pain science","nociplastic pain","2026-08-14",{"date":127,"type":44},"2026-08-18",{"date":129,"type":44},"2025-01-02",{"date":131,"type":21},"2026-12-31",{"name":133,"class":51},"Kutahya Health Sciences University",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":52},"100645543","prt-for-chronic-low-back-pain-100645543","NCT07696741","PRT for Chronic Low Back Pain","Pain Reprocessing Therapy for Chronic Low Back Pain: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Working age adults (18-65)\n* Male or Female at birth\n* Persisting back pain for at least 3 months occurring at least half of the days in the past 6 months\n* Pain score of at least 4\u002F10 (on a 10-point rating scale)\n* Ability to speak and understand English in order to follow study procedures and engage in study interventions.\n\nExclusion Criteria:\n\n* Compensation seeking claim\u002Flitigation\u002FWSIB claim\n* Severe active psychiatric disorders (e.g., psychosis, substance use disorder)\n* An active medical issue such as untreated inflammatory disorder (e.g. ankylosing spondylitis, psoriatic arthritis)\n* Active cancers affecting the spine or body\n* Unexplained unintended weight loss of 20 lbs. or more in the past year\n* Inability to control bowel or bladder, function\n* Individuals who have received or are currently receiving one-on-one or group psychotherapy for chronic low back pain within the past 2 years (e.g., mindfulness, meditation, cognitive behavioural therapy, acceptance and commitment therapy, pain reprocessing therapy, or emotional awareness and exposure therapy).\n* Logistical or technical barriers (e.g. transportation challenges, scheduling constraints, or difficulty using fitness trackers",{"count":142,"type":21},30,[24],"The goal of this clinical trial is to learn whether Pain Reprocessing Therapy (PRT) is a feasible and acceptable treatment to complete for working-age adults (ages 18-65) with chronic low back pain. The main questions it aims to answer are:\n\nIs PRT acceptable and feasible for people with chronic low back pain to complete? Does PRT help reduce pain intensity and interference, while improving functional outcomes in people with chronic low back pain?\n\nResearchers will compare PRT to a Monitoring and Education Program to see whether participants who receive PRT experience greater improvements in pain, daily functioning, and well-being.\n\nParticipants will:\n\n* Be randomly assigned to the PRT group or the Monitoring and Education group\n* Participate in 8 intervention sessions over an 8-week period\n* Wear an activity monitor for 8 weeks\n* Attend a follow-up assessment after completing the intervention and another assessment 3 months later\n\nPlease note that ClinicalTrials.gov will be used solely as a public study registry and not as a participant recruitment tool. The study team will not recruit participants or accept self-referrals through ClinicalTrials.gov. All participant recruitment will occur only through the Research Ethics Board (REB) approved recruitment methods.",[68,146],"Nociplastic Pain",[148,149,146,150,151,152,27,153,154],"Chronic Pain","Back Pain","Pain Management","Randomized Controlled Trial","Mind-Body Therapies","Rehabilitation","Pilot Projects",{"date":41,"type":44},{"date":157,"type":44},"2026-07-15",{"date":159,"type":21},"2027-06",{"name":161,"class":51},"University Health Network, Toronto",{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":52},"100649311","combined-and-aquatic-exercise-in-chronic-low-back-pain-100649311","NCT07732595","Combined and Aquatic Exercise in Chronic Low Back Pain","Effects of Combined-exercise and Aquatic-exercise on Pain, Disability and Functional Capacity in Patients With Chronic Low Back Pain","Inclusion Criteria:\n\n* all genders;\n* aged over 18 years;\n* Chronic Low Back Pain lasting three months or longer and with an intensity of 3 or higher on the Visual Analogue Scale at rest.\n\nExclusion Criteria:\n\n* Individuals who refuse to participate or do not provide informed consent;\n* Pain radiating to the lower limb;\n* Recent pregnancy or childbirth (less than 8 weeks ago);\n* Ongoing physical therapy treatments;\n* Severe rheumatological, neurological, neoplastic, cardiovascular diseases or other conditions that could prevent full participation in the intervention;\n* History of spinal surgery;\n* Inflammatory, infectious, or malignant spinal diseases;\n* Psychiatric disorders that may affect adherence and symptom assessment.",{"count":170,"type":21},90,[24],"The goal of this randomized clinical trial is to evaluate the effects of a combined aquatic- and land-based exercise program, as well as an aquatic-exercise program, compared with a control group receiving home-based exercise, on pain, disability, and functional capacity in adults with CLBP. Secondary objectives include examining the effects on fear of movement, anxiety and depression, quadriceps and hand-grip strength, and lumbar mobility. The main question it aims to answer is: \"Which type of exercise program is most effective at improving pain, disability, functional capacity, fear of movement, anxiety and depression, quadriceps and hand-grip strength, and lumbar mobility in adults with chronic low back pain?\".\n\nParticipants will perform an aquatic-based exercise program (aquatic group), a combined aquatic and land-based exercise program (aquatic and land group), or a land-based exercise program (home group).\n\nResearchers will compare groups to find any differences in pain, disability, functional capacity, kinesiophobia, anxiety and depression, quadriceps and hand-grip strength, and lumbar mobility.",[28],[149,175,176,177,178],"Disability","Exercise","Aquatic Therapy","Physical Capacity","2026-07-28",{"date":181,"type":44},"2026-07-30",{"date":183,"type":21},"2026-09",{"date":185,"type":21},"2027-05",{"name":187,"class":51},"University of Beira Interior",{"id":189,"slug":190,"hasResults":12,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":198,"conditions":199,"keywords":201,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":52},"100645128","comparing-non-medicine-strategies-for-improving-low-back-pain-100645128","NCT07679178","Comparing Non-Medicine Strategies for Improving Low Back Pain","Comparing Strategies to Improve Non-Pharmacologic Pain Relief for Adults With Back Pain (The ENCompaSS Trial)","Inclusion Criteria:\n\n* Be age 18 years old or older\n* Have a VA outpatient clinic visit for low back pain within the previous 30 days\n* Be enrolled in a participating primary care clinic\n* Have high impact chronic pain per Graded Chronic Pain Scale (most days or every day on first 2 items)\n* Valid telephone access\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Are currently hospitalized or residing in a nursing home\n* Have cognitive impairment or lack of decision-making capacity\n* Have a serious mental illness (e.g., schizophrenia, bipolar disorder, recent psychiatric hospitalization, high risk suicide flag)\n* Are unable to communicate by telephone or have no telephone access",{"count":196,"type":21},530,[24],"The goal of this clinical trial is to help veterans manage high-impact chronic pain (HICP) in the lower back. The trial will use a program, ENCompaSS (Education, Navigated Care, and Supported Self-Management) designed to reduce pain more than usual care alone. Researchers will assess a) the impact of ENCompaSS, b) identify which veterans benefit the most, and c) how this program can be delivered more broadly in other clinics and health systems.\n\nWhat Will Happen:\n\nVeterans in this clinical trial will be randomly placed into one of two groups.\n\nENCompaSS group (intervention):\n\n* Have at least three phone calls with a trained clinician over about 12 weeks\n* Watch short online videos about managing pain\n* Complete surveys before the study and again at 2, 4, 6, and 12 months\n\nUsual Stepped Care group:\n\n* Will continue with regular care\n* Complete the same surveys at the same time points",[28,200],"High-Impact Chronic Pain (HICP)",[202,27,203,150,204],"Veterans","Clinical Pathway","Non-Pharmacologic","2026-07-27",{"date":179,"type":44},{"date":102,"type":21},{"date":209,"type":21},"2029-07-31",{"name":211,"class":51},"Duke University",{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":220,"targetDuration":4,"studyType":22,"phases":221,"briefSummary":222,"conditions":223,"keywords":233,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":52},"100622663","biologic-injection-for-adults-with-lumbar-disc-herniation-100622663","NCT07386548","Biologic Injection For Adults With Lumbar Disc Herniation","Bone Marrow Aspirate Concentrate Injection With MRI's - A Prospective Randomized Control Trial","BMAC","Inclusion Criteria:\n\n* Male or female patients ≥ 18 years of age\n* Clinically and\u002For radiographically (MRI) confirmed diagnosis of degenerative disc disease of the lumbar spine, lumbar disc herniation, and indication for lumbar microdiscectomy surgery\n* Unresponsive to conservative\u002Fnon-operative treatment for \\>3 months\n* Psychosocial, mental and physical ability to understand and to adhere to this protocol, especially adhering to the visit schedule follow-ups and observe the treatment plan\n\nExclusion Criteria:\n\n* Prisoners\n* Individuals who are not yet adults (infants, children, teenagers)\n* Individuals who are not able to clearly understand English\n* Adults with diminished capacity to consent\n* Major cognitive impairment causing to inability to understand and provide informed consent\n* Active malignancy\n* Active chronic or acute infection\n* Autoimmune disorder that impacts the lumbar spine (ankylosing spondylitis, lupus e.g.)\n* Bone marrow-derived or non-bone marrow-derived cancer\n* Low platelet count or clotting disorders\n* Prior surgery at the level to be treated or the adjacent level",{"count":170,"type":21},[24],"The goal of this clinical trial is to find out whether adding a bone-marrow aspirate concentrate (BMAC) injection during surgery can improve recovery in adults undergoing lumbar microdiscectomy for a lumbar disc herniation.\n\nThe main questions it aims to answer are:\n\n* Does the BMAC injection lead to better disc tissue health after surgery (as seen on MRI scans)?\n* Does the BMAC injection lead to greater improvement in pain and disability compared to surgery alone?\n\nParticipants will be adults aged 18 and older who are scheduled for lumbar microdiscectomy surgery.\n\nResearchers will compare one group of participants receiving the standard-of-care surgery plus the BMAC injection with another group receiving the same surgery without the injection to see if the injection offers added benefit.\n\nParticipants will:\n\n* Have surgery (microdiscectomy) with or without the injection.\n* Complete pain and disability questionnaires at several times over 2 years.\n* Undergo MRI scans at baseline and follow-up to assess disc structure and tissue health.\n* Provide samples of leftover disc or bone-marrow tissue (as applicable) from surgery for analysis.",[224,225,226,227,228,229,230,231,27,68,232],"Degenerative Disc Disease","DDD","Degenerative Disc Disease Lumbar","Degenerative Disc Disease, Lumbar","Lumbar Disc Herniation","Disc Herniation, Lumbar","Bone Marrow Aspirate Concentrate","Intervertebral Disc Displacement","CLBP - Chronic Low Back Pain",[234,235,236,237,238],"degenerative disc disease","lumbar disc herniation","bone marrow aspirate concentrate","intervertebral disc displacement","low back pain",{"date":240,"type":44},"2026-07-29",{"date":242,"type":21},"2026-08-30",{"date":244,"type":21},"2030-12",{"name":246,"class":51},"Weill Medical College of Cornell University",{"id":248,"slug":249,"hasResults":12,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":61,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":254,"targetDuration":4,"studyType":22,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":52},"100649412","chronic-low-back-pain-comorbidities-unravelling-impaired-glucose-metabolism-100649412","NCT07734714","Chronic Low Back Pain Comorbidities: Unravelling Impaired Glucose Metabolism","GLOW","Inclusion Criteria:\n\n* Between 18 and 65 years old\n* For patient group: participants must comply to the non-specific CLBP criteria which are low back pain every day for three months or pain for at least half the days in the last six months, without leg pain that exceeds 7 out of 10 on a numeric rating scale and without evidence of specific spinal pathologies.\n* For healthy volunteers: pain-free for the entire duration of the study\n\nExclusion Criteria:\n\n* Systemic diseases (e.g., hypertension, cardiovascular disease, chronic gastrointestinal disorder, skin disease, active neuropathic disorder, severe eating disorders, myocardial infarction or cerebrovascular accident in the 6 months prior to the study)\n* Current pregnancy or pregnancy in the last year\n* Start-up of new medication or (dietary) treatment in the six weeks before the study\n* Antibiotic use in the three months prior to the study\n* History of bariatric surgery\n* Use of analgesics, alcohol, immunosuppressive drugs or smoking 48 hours prior to study participation\n* Classified as diabetic according to the American Diabetes criteria: fasting blood glucose ≥ 126 mg\u002Fdl, blood HbA1c ≥ 6.5%, or 2-hour PPGR ≥ 200 mg\u002Fdl\n\nAdditionally, study participation will be postponed in case the participant donated blood \\\u003C 8 weeks before baseline and participants will be asked not to donate blood for the duration of the trial.",{"count":255,"type":21},124,[24],"Chronic low back pain (CLBP) is a global health problem. The first step for developing effective treatments is a better understanding of underlying mechanisms, including its comorbidities. Cumulative findings, including breakthrough findings from our own group, point to impaired glucose metabolism as an important CLBP comorbidity. In addition to its metabolic role, the insulin-like growth factor 1 (IGF1)\u002F growth hormone (GH) axis plays a key role in pain modulation. Therefore, the project aims to examine whether DNA methylation and functional protein levels predicts postprandial glycemic responses to standardized drinks, standardized meals, and real-life meals in patients with CLBP. This will be examined using two (i.e., 1 in CLBP and 1 in healthy controls) double-blind, randomized cross-over experiments (high versus low glycaemic index beverages). After the 14-day experimental phase, all participants will be studied for an additional week to examine whether the experimental findings have ecological validity, i.e., whether they can be confirmed in response to real-life meals in their home environment. Genome-wide changes in DNA methylation will be studied using whole genome bisulfite sequencing and targeted next-generation sequencing. The project allows identification of a biomarker for a potentially very significant CLBP comorbidity, including identifying targetable mechanisms to develop innovative, personalized treatments.",[259,68],"Chronic Low Back Pain (Non-specific, Uncomplicated)",[261,262,263,264,265,266],"Epigenetic","DNA methylation","Glucose metabolism","IGF1\u002FGH axis","Chronic low back pain","CLBP","2026-07-23",{"date":240,"type":44},{"date":270,"type":21},"2026-07",{"date":272,"type":21},"2030-04",{"name":274,"class":51},"Vrije Universiteit Brussel",{"id":276,"slug":277,"hasResults":12,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":285,"conditions":286,"keywords":288,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":300,"leadSponsor":302,"locationsCount":52},"100649215","impact-of-the-receptive-music-intervention-tool-music-care-on-changes-in-the-functional-abilities-of-patients-with-chronic-low-back-pain-100649215","NCT07731204","Impact of the Receptive Music Intervention Tool (MUSIC CARE©) on Changes in the Functional Abilities of Patients With Chronic Low Back Pain","LOMBALZIC'","Inclusion Criteria:\n\n* Diagnosed with chronic low back pain by a Physical Medicine and Rehabilitation (PMR) physician, defined as lumbar pain and\u002For pain radiating to the lower limb that affects daily and professional activities and has lasted more than 3 months\n* If surgery was performed, it must have been done at least 3 months before entering the study\n* Adult (18 years of age or older) admitted to the day hospital at Clinique Saint-Roch for a chronic low back pain rehabilitation program\n* Considered able to return to work, as assessed by the PMR physician during the pre-admission consultation, with no medical contraindication to resuming professional activity\n* Affiliated with a French social security scheme\n* Has given written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Hearing impairment that would prevent the use of the MUSIC CARE© device\n* Medical contraindication to hydrotherapy (balneotherapy)\n* Symptomatic disc herniation\n* Vertebral fracture or history of recent vertebral fracture within the past 2 years\n* Unstable spondylolisthesis\n* Disc-vertebral infection (spondylodiscitis)\n* Inflammatory rheumatic disease such as ankylosing spondylitis (spondyloarthritis) or rheumatoid arthritis\n* Constitutional connective tissue disorder such as Ehlers-Danlos syndrome or Marfan syndrome\n* Severe, unstabilized, or decompensated psychiatric disorder, including psychotic disorders, acute-phase bipolar disorder, or severe major depressive episode\n* Central nervous system neurological disease such as multiple sclerosis, stroke, or Parkinson's disease\n* Peripheral neuropathy of the lower limbs\n* Unstabilized cardiovascular disease\n* Active cancer treatment or cancer diagnosis within the past 2 years\n* Surgery for a reason other than low back pain within the past 6 months\n* Currently retired (not in active employment)\n* Currently enrolled in another interventional research study\n* Persons under legal protection as defined by Articles L.1121-5 to L.1121-8 of the French Public Health Code, including:\n* Persons under guardianship, curatorship, or judicial protection\n* Minors (under 18 years of age)\n* Pregnant or breastfeeding women\n* Any person subject to a legal protection measure or unable to freely provide informed consent",{"count":283,"type":21},34,[24],"Brief Summary The goal of this clinical trial is to learn if MUSIC CARE©, a music-based therapy tool, can improve the physical abilities of people with chronic low back pain (back pain that lasts more than 3 months).\n\nThe main questions it aims to answer are:\n\nDoes MUSIC CARE© help participants better perform their daily activities? Does MUSIC CARE© lower the fear of movement in participants? Does MUSIC CARE© help participants return to work?\n\nWhy this study? Chronic low back pain is a leading cause of disability and absence from work. Physical rehabilitation is the recommended treatment. However, many participants develop a fear of movement. This fear slows down their recovery and limits the benefits of rehabilitation.\n\nMUSIC CARE© is a digital music tool. It uses specially designed music to help participants relax and feel less pain. Researchers believe that using MUSIC CARE© before rehabilitation sessions may help participants move more freely and recover better.\n\nHow does the study work?\n\nResearchers will compare two groups of participants:\n\nGroup 1: follows a standard rehabilitation program with MUSIC CARE© Group 2: follows a standard rehabilitation program without MUSIC CARE© This comparison will show whether MUSIC CARE© brings added benefits.\n\nParticipants will:\n\nTake part in a rehabilitation program for 5 to 6 weeks Use MUSIC CARE© before each therapy session (Group 1 only). Complete questionnaires about their pain, fear of movement, and ability to perform daily activities.\n\nBe followed for 6 months after the program ends, including an assessment of their return to work.\n\nWhat could this study change? If results are positive, this study could confirm that MUSIC CARE© is a useful non-drug tool to support rehabilitation for people with chronic low back pain. It could help bring this approach into standard care programs, with no additional medication.",[27,287,28],"Kinesiophobia (Fear of Movement)",[27,148,289,290,291,292,153,293,294,295,296,297],"Music Therapy","Physical Functional Performance","Kinesiophobia","Fear of Movement","Exercise Therapy","Return to Work","Non-Pharmacological Intervention","Patient Reported Outcome Measures","Functional Capacity",{"date":179,"type":44},{"date":46,"type":21},{"date":301,"type":21},"2027-12",{"name":303,"class":51},"LNA SANTE",{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":311,"targetDuration":4,"studyType":22,"phases":313,"briefSummary":314,"conditions":315,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":52},"100647720","magnetic-resonance-elastography-of-chronic-low-back-pain-before-and-after-therapy-100647720","NCT07712458","Magnetic Resonance Elastography Of Chronic Low Back Pain Before And After Therapy","Magnetic Resonance Elastography Assessment Of Chronic Low Back Pain Before And After A Manual Therapy Intervention","Inclusion Criteria:\n\n* Adult males or females (age ≥ 18 years)\n* Report chronic low back pain (≥3 months) (measured by patient history and clinical evaluation)\n* Pain intensity reported at baseline must be ≥4 on the pain VAS scale\n* Presence of myofascial pain features in the lumbar region (e.g., localized tenderness and\u002For trigger points identified by a qualified clinician\u002Ftherapist)\n* Able to lie in supine and prone positions for study procedures\n* Be able to participate fully in all aspects of the study\n* Have understood and signed study informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Patients with the inability to stay in a prone and supine position for the required procedure durations (e.g., ≥30 minutes at a time)\n* Any contraindication to an MRI exam, or severe claustrophobia that would prevent safe completion of the scan\n* Previous lumbar spine surgery or history of severe lumbar injury (e.g., fracture) that, in the investigation team's judgment, would interfere with participation or safety\n* Patients with known bleeding disorders or current therapeutic anticoagulation that would increase risk of bruising\u002Fbleeding with massage\n* Patients with skin conditions affecting the treatment area (e.g., rash, open wound, active dermatitis) or known allergy to any materials used during treatment (e.g., gels\u002Fcleaners), if applicable\n* Receipt of a new pain treatment within 3 days of the study visit (e.g., injection, ablation, spinal manipulation, massage\u002Fmanual therapy) that could confound pre\u002Fpost measures\n* Use of short-acting opioid analgesics or sedating medications within 24 hours of the study visit\n* Have an implanted device in or near the treatment area that could interfere with safe application of external pressure\n* Have used an investigational drug within 30 days of study enrollment\n* History of any major cardiovascular events including heart valve disease, ongoing angina, cardiac arrhythmias, congestive heart failure, acute coronary syndrome, stroke, transient ischemic attack, or peripheral vascular disease.\n* Clinically significant unstable neurologic or systemic illness that would preclude safe participation, as judged by the investigation team.\n* Surgical intervention for pain within 1 month prior to enrollment\n* Active infection, wound, or other external trauma to the areas to be treated\n* Have a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence\n* Inability to provide consent",{"count":312,"type":21},38,[24],"The purpose of this study is to quantify Magnetic Resonance Elastography (MRE)-derived mechanical property biomarkers of the lumbar paraspinal musculature and associated myofascial tissue regions before and after the intervention.",[316,68],"Low Back Pain, Recurrent","2026-07-20",{"date":319,"type":44},"2026-07-22",{"date":321,"type":21},"2026-08-01",{"date":323,"type":21},"2028-08-01",{"name":325,"class":51},"Mayo Clinic",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":17,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":22,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":52},"100645629","effects-of-vacuum-controlled-static-versus-vacuum-controlled-dynamic-dry-cupping-on-pain-range-of-motion-and-disability-among-patients-with-chronic-low-back-pain-100645629","NCT07702617","Effects Of Vacuum Controlled Static Versus Vacuum Controlled Dynamic Dry Cupping On Pain, Range Of Motion And Disability Among Patients With Chronic Low Back Pain","Inclusion Criteria:\n\n* Age 30 to 40 years. (21)\n* Both male and female genders (15)\n* Patients experiencing LBP with a score of at least 3\u002F10 on the NPRS (22)\n* For more than three months (22).\n* Individuals whose workstations have not been ergonomically designed and who have not previously received structured ergonomic interventions related to workplace layout, task design, or load modification also involving home tasks and daily activities. (31)\n\nExclusion Criteria:\n\n* \\* Subjects with lower body condition (i.e., spondylolisthesis, spinal stenosis, osteoporosis, or intervertebral disk derangement) (15)\n\n  * Subjects with a history of cancer (15)\n  * Subjects experiencing referred leg symptoms (15)\n  * Subjects with any current local or systemic infections, vascular disease, including varicose veins (17)\n  * History of spine surgery or spinal tumor (17).","30 Years","40 Years",{"count":335,"type":21},48,[24],"This randomized controlled clinical trial aims to compare the effects of vacuum-controlled static dry cupping and vacuum-controlled dynamic dry cupping on pain intensity, lumbar range of motion, and functional disability in patients with chronic low back pain. Participants will be randomly assigned to two groups receiving either static or dynamic dry cupping along with conventional treatment. The outcomes will be assessed to determine which cupping technique is more effective in improving pain, mobility, and functional ability in individuals with chronic low back pain.\n\n\\[Time Frame: Measured at baseline (pre-intervention) and after 6 weeks (post-intervention completion).",[28],{"date":319,"type":44},{"date":341,"type":21},"2026-07-01",{"date":343,"type":21},"2026-11-30",{"name":345,"class":51},"Lahore University of Biological and Applied Sciences",{"id":347,"slug":348,"hasResults":12,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":354,"maxAge":4,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":360,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":372,"leadSponsor":374,"locationsCount":377},"100646125","spinery-basivertebral-nerve-ablation-for-vertebrogenic-chronic-low-back-pain-100646125","NCT07696507","Spinery Basivertebral Nerve Ablation for Vertebrogenic Chronic Low Back Pain","Clinical Study of a RadioFrequency Basivertebral Nerve Ablation Device (Spinery® RF Generator and Its Sterile Single-use Accessories - the Spinery® Kit and the Spinery® Cooling Connection) for Chronic Low Back Pain (CLBP) Treatments","BASILEA","Inclusion Criteria:\n\n1. Male or female skeletally mature participants aged 25 years or older.\n2. Chronic low back pain for at least 6 months.\n3. Failure to respond to at least 6 months of non-operative conservative care.\n4. Oswestry Disability Index (ODI) score at time of evaluation of at least 30 points.\n5. Baseline Visual Analogue Scale (VAS) pain score of at least 4 cm on a 10 cm scale.\n6. Modic type 1 changes, or Modic type 2 changes only when associated with edema-like signal changes on T2\u002FSTIR sequences, in at least one vertebral endplate at one or more levels from L3 to S1, confirmed by MRI and considered clinically concordant with vertebrogenic low back pain.\n7. No radiological evidence of impending vertebral fracture or structural instability at the planned treatment level(s).\n8. Able to read, write, speak, and understand the Italian language; willing and able to provide signed and dated informed consent; and willing and able to comply with the study plan, follow-up visits, and scheduled study contacts.\n\nExclusion Criteria:\n\n1. History or evidence within the past 12 months of radicular pain, radiculopathy, or clinically relevant neuropathic deficit.\n2. Planned treatment in more than three adjacent vertebrae in the same procedure.\n3. Current or history of symptomatic spinal canal stenosis, vertebral cancer, spinal metastasis, or spinal infection.\n4. Any MRI or other imaging evidence of alternative or additional clinically relevant lumbar pathology that could explain the participant's pain or confound study outcomes, such as:\n\n   * nerve root compression, neurogenic claudication, or severe thecal sac effacement correlating with radicular pain, neurologic symptoms, or muscle weakness;\n   * disc herniation, protrusion, extrusion, or other disc pathology at any lumbar level when clinically correlated with radicular pain or neurologic findings;\n   * facet arthrosis or facet effusion at any lumbar level correlating with clinical evidence of facet-mediated low back pain;\n   * spondylolisthesis greater than or equal to 2 mm at any lumbar level;\n   * spondylolysis at any level.\n5. Previous lumbar spine surgery considered by the Investigator to interfere with target interpretation, procedural feasibility, or study endpoint evaluation.\n6. Osteoporosis, defined as T-score less than or equal to -2.5.\n7. Metabolic bone disease, such as osteogenesis imperfecta.\n8. Multiple myeloma, solitary plasmacytoma, or primary malignant lesions in the index vertebra or bone.\n9. Active or incompletely treated local infection at the planned treatment site(s) and\u002For systemic infection.\n10. Planned treatment site(s) accompanied by objective evidence of secondary radiculopathy or neurologic compromise attributable to a cause other than vertebrogenic pain.\n11. Body mass index (BMI) greater than or equal to 40.\n12. Planned treatment site(s) associated with clinically relevant radicular compression and\u002For spinal canal compromise requiring surgical decompression.\n13. Contraindication to MRI, or known allergy\u002Fhypersensitivity to any material or component relevant to the investigational procedure.\n14. Pregnant, breastfeeding, or planning to become pregnant during the study duration.\n15. Concurrent participation in another clinical study that may add additional safety risks and\u002For confound study results.\n16. Any condition that would interfere with the participant's ability to comply with study instructions or might confound study interpretation.\n17. Any medical condition that may substantially interfere with follow-up or confound pain and disability assessment, such as fibromyalgia, rheumatoid arthritis, chronic regional pain syndrome, or reflex sympathetic dystrophy.\n18. Implantation with a heart pacemaker or another implanted electronic device.\n19. Evidence of substance abuse or dependence, or use of prescribed extended-release narcotics within the 3 months prior to screening that, in the Investigator's judgment, may interfere with pain assessment, study compliance, or interpretation of study outcomes.","25 Years",{"count":356,"type":21},69,[24],"The goal of this clinical trial is to learn whether the Spinery® RF Generator and its sterile single-use accessories can safely lower disability and pain in adults with long-term low back pain that is thought to come from changes inside the vertebral bones of the lower spine. This type of pain is called vertebrogenic chronic low back pain.\n\nThe study will include adults whose low back pain has lasted for at least 6 months and has not improved enough with non-surgical care. Participants must also have specific changes on spine magnetic resonance imaging (MRI), called Modic type 1 changes or selected Modic type 2 changes, at one or more levels between L3 and S1.\n\nThe main questions this study aims to answer are:\n\n* Does the treatment improve daily function 3 months after the procedure?\n* Does the treatment lower low back pain?\n* Does the treatment improve quality of life?\n* What medical problems happen during or after the procedure?\n* Does the 6-week MRI show that the treatment reached the intended area inside the vertebra?\n\nAll participants will receive treatment with the Spinery® RF Generator and accessories. There is no untreated comparison group. Participants will be assigned by chance to one of three ways of performing the radiofrequency ablation procedure. Radiofrequency ablation uses controlled heat to treat a small target area. In this study, the target is the basivertebral nerve, a nerve inside the vertebral body that may contribute to low back pain in some people.\n\nParticipants will:\n\n* have screening tests, including spine MRI;\n* complete questionnaires about pain, daily function, and quality of life;\n* undergo the radiofrequency ablation procedure with the Spinery® RF Generator and accessories;\n* have an MRI about 6 weeks after treatment;\n* attend follow-up visits at 3 months and 6 months;\n* report any medical problems or changes in pain treatment during the study.",[27,68],[361,362,363,364,365,366,352,367],"Basivertebral Nerve Ablation","Radiofrequency Ablation","Vertebrogenic Pain","Modic Changes","Oswestry Disability Index","Spinery","Minimally Invasive Spine Procedure","2026-07-09",{"date":370,"type":44},"2026-07-10",{"date":183,"type":21},{"date":373,"type":21},"2028-03",{"name":375,"class":376},"Axon srl","INDUSTRY",3,{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":384,"eligibilityCriteria":385,"healthyVolunteers":61,"sex":17,"minAge":386,"maxAge":4,"enrollmentInfo":387,"targetDuration":4,"studyType":22,"phases":389,"briefSummary":390,"conditions":391,"keywords":392,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":52},"100645758","impairment-based-treatment-versus-modified-functional-restoration-program-in-chronic-low-back-pain-patients-100645758","NCT07699419","Impairment Based Treatment Versus Modified Functional Restoration Program in Chronic Low Back Pain Patients","FIRM-CLBP: a Randomized Controlled Feasibility Trial Comparing Impairment-based Treatment With a Modified Functional Restoration Program in Older Adults With Chronic Low Back Pain","FIRM-CLBP","Inclusion Criteria:\n\n* ≥ 60 years\n* Chronic Non-Specific Low Back Pain (CNSLBP)\n* Pain duration ≥ 12 weeks\n* No identifiable specific spinal pathology\n* Pain Location\n* Pain localized between the 12th rib and gluteal folds\n* With or without non-dermatomal referred pain not extending below the knee\n* Pain Intensity\n* Mean pain intensity ≥ 4\u002F10 on the Numeric Rating Scale (NRS) over the past 7 days\n* Functional Disability\n* Oswestry Disability Index (ODI) ≥ 20% (moderate disability or higher)\n* Mechanical Pain Characteristics\n* Presence of ≥ 2 of the following:\n* Pain aggravated by movement, loading, or prolonged postures\n* Pain relieved by rest or positional change\n* Morning stiffness \\\u003C 30 minutes\n* Absence of constant, non-mechanical night pain Functional Capacity\n* Able to ambulate independently (with or without assistive device)\n* Able to actively participate in an exercise-based rehabilitation program\n* Clinical Stability\n* Stable medication regimen (analgesics, anti-inflammatories, or related drugs) for ≥ 4 weeks\n* No planned changes in pharmacological treatment during the study period\n* Cognitive \\& Communication Ability\n* Able to understand study procedures and follow instructions\n* MMSE ≥ 24 (or equivalent cognitive screening)\n* Consent\n* Provides written informed consent\n\nExclusion Criteria:\n\n* 1\\. Specific Spinal Pathology (\"Red Flags\")\n\n  * Suspected or confirmed:\n  * Spinal fracture\n  * Malignancy\n  * Spinal infection\n  * Inflammatory spondyloarthropathy\n\nClinical indicators:\n\nUnexplained weight loss Fever or systemic illness History of significant trauma\n\n2\\. Radicular or Neurological Involvement\n\n* Radiculopathy defined by ANY of:\n* Dermatomal pain radiating below the knee\n* Progressive motor weakness\n* Objective neurological deficit (sensory, reflex, or motor)\n\n  3\\. Lumbar Spinal Stenosis (Severe)\n* Neurogenic claudication limiting walking to \\\u003C 100 meters, OR\n* Symptoms not relieved by rest or flexion\n\n  4\\. Prior Surgical or Structural Conditions Lumbar spine surgery within the past 12 months\n\n  5\\. Medical Contraindications to Exercise\n* Severe osteoporosis with high fracture risk\n* Uncontrolled cardiovascular, respiratory, or metabolic disease\n* Any condition precluding safe participation in rehabilitation\n\n  6\\. Cognitive or Behavioral Barriers\n* Severe cognitive impairment (MMSE \\\u003C 24)\n* Inability to comply with study procedures\n\n  7\\. Confounding Treatment Factors\n* Participation in structured physiotherapy or rehabilitation within the past 3 months\n* Planned concurrent rehabilitation during the study\n\n  8\\. Psychosocial Confounders Ongoing litigation or compensation claims related to low back pain","60 Years",{"count":388,"type":21},18,[24],"The aim of this feasibility study is to evaluate the practicality of conducting a future randomized controlled trial comparing two rehabilitation approaches for older adults with degenerative chronic low back pain: impairment-based treatment (IBT) and a modified short Functional Restoration Program (FRP).\n\nImpairment-based treatment is an individualized approach in which interventions are tailored to the patient's specific physical deficits, such as limitations in mobility, strength, and motor control. In contrast, the Functional Restoration Program is a structured, standardized approach focusing on improving overall functional capacity through progressive exercise, movement retraining, and activity-based rehabilitation.\n\nParticipants will be randomly allocated to one of the two groups. Both interventions will be delivered by trained physiotherapists following standardized protocols over a 6-week period, with supervised sessions conducted according to a predefined rehabilitation schedule.",[68],[393,394,395,396],"LBP","Old age","Impairment","Functional","2026-07-07",{"date":399,"type":44},"2026-07-13",{"date":341,"type":21},{"date":402,"type":21},"2027-01-10",{"name":404,"class":51},"Cairo University",{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":419,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":426,"lastUpdatePostDateStruct":427,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":432,"locationsCount":52},"100630937","imaging-metabolic-and-perfusion-changes-in-acupuncture-therapy-for-myofascial-pain-syndrome-100630937","NCT07494162","Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS: Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","IMPACT-MPS","Inclusion Criteria:\n\n* Ability to understand the purposes and risks of the trial and willingness to sign an informed consent form\n* Willingness and ability to comply with all protocol required procedures\n* Willingness to be randomized to receive either true acupuncture or sham acupuncture\n* Current self-report of chronic low back pain (cLBP) which has persisted for the past 3 months AND has resulted in pain on \\> 50% of days in the past 6 months\n* At least one palpable nodule or taut band in paraspinal, quadratus lumborum, or gluteal muscles\n* Reproduction of the patient's dominant pain with palpation of a muscle nodule or taut band\n* Predominantly paramedian pain (may be uni-lateral or bi-lateral)\n* Willing and able to lay motionless in a supine position at least twice, preferably thrice: 70-minute TB-PET\u002FCT scan\n* Willing and able to fast for at least 6 hours before and for the duration of the TB-PET\u002FCT scan\n* Willing to avoid strenuous exercise for 24 hours before the TB-PET\u002FCT scan visit\n* Willingness to practice effective contraception during the study.\n\nExclusion Criteria:\n\n* No Primary Care Physician\n* History of spine infection (discitis or osteomyelitis) or spine tumor\n* History of ankylosing spondylitis, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, or lupus\n* Confounding conditions that are known to be responsible for inducing pain\n* Implants at or in the region of the sites of interest\n* Diagnosis of any vertebral fracture in the last 6 months\n* Cauda equina syndrome or lumbar radiculopathy with functional motor deficit (strength\\\u003C4\u002F5 on manual motor testing)\n* Spinal implants (including fixation hardware, spinal cord stimulator, intra-thecal pumps, that are present in the region of the sites of interest)\n* Predominantly central pain\n* Pain below the knee\n* Positive straight leg raise test\n* Symptomatic hip arthritis\n* Uncontrolled claustrophobia\n* Pregnant or lactating participants\n* Body weight more than 225 kg (496 pounds) due to the weight limitation of the scanner bed\n* Prisoners\n* Inability to speak, read, and write in the English language\n* Concurrent or prior enrollment in a separate research study involving a PET scan performed within the last 12 months for research purposes only.\n\nThat is, PET scans are not performed as part of a patient's treatment plan (e.g. standard of care, therapeutic purposes, or clinical care) and the research study did not intend to provide therapeutic benefit to the patient.\n\n•Any other criteria, which would make the participant unsuitable to participate in this study as determined by the Principal Investigator",{"count":414,"type":21},64,[24],"This study will evaluate the clinical and biological effects of acupuncture for chronic low back pain associated with myofascial pain syndrome (MPS).\n\nIn this randomized, participant- and assessor-blinded clinical trial, 64 adults with chronic low back pain due to MPS will be assigned to receive either true acupuncture or sham acupuncture for eight weeks. Participants will undergo total-body positron emission tomography\u002Fcomputed tomography (TB-PET\u002FCT) imaging and complete standardized pain and functional questionnaires at baseline and after treatment.\n\nThe study will evaluate whether acupuncture improves pain and function compared with sham treatment and whether TB-PET\u002FCT imaging can detect changes in myofascial tissue metabolism and perfusion that correspond with clinical outcomes.",[418,28],"Myofascial Pain Syndrome (MPS)",[420,421,422,423,424,425],"acupuncture treatment","Total-Body PET","FDG PET","Myofascial Pain Syndrome","Chronic Low Back Pain","Imaging Biomarkers","2026-06-15",{"date":428,"type":44},"2026-06-17",{"date":430,"type":44},"2026-05-18",{"date":272,"type":21},{"name":433,"class":51},"University of California, Davis",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":442,"enrollmentInfo":443,"targetDuration":4,"studyType":22,"phases":445,"briefSummary":446,"conditions":447,"keywords":448,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":458,"locationsCount":52},"100642277","focal-extracorporeal-shock-wave-therapy-with-two-different-dosing-regimens-for-chronic-low-back-pain-100642277","NCT07646132","Focal Extracorporeal Shock Wave Therapy With Two Different Dosing Regimens for Chronic Low Back Pain","Effects of Two Dosing Regimens of Focal Extracorporeal Shock Wave Therapy in Patients With Chronic Low Back Pain: A Randomized Clinical Trial","ESWT-LBP","Inclusion Criteria:\n\n* Individuals of both sexes.\n* Age between 18 and 65 years.\n* Clinical diagnosis of mechanical chronic low back pain (cLBP), defined as pain localized between the lower costal margin and the gluteal fold, with at least 12 weeks of evolution.\n* Lumbar pain intensity of at least 5\u002F10 on the Numeric Pain Rating Scale (NPRS).\n* Predominantly mechanical pain, exacerbated by activities such as prolonged standing, trunk movements, extension, or lumbar rotation, and without clinical data of predominant radicular pain.\n* Plain radiograph of the lumbar spine available as part of the baseline evaluation.\n* Ability to attend all 4 treatment sessions and subsequent follow-up evaluations.\n* Signed informed consent form previously approved by the Institutional Review Board \u002F Research Ethics Committee.\n\nExclusion Criteria:\n\n* Low back pain of probable non-mechanical origin or secondary to a specific cause that substantially modifies clinical management.\n* Clinical data of predominant lumbar radiculopathy, including pain radiating below the knee with a dermatomal distribution, focal motor deficit, objective sensory alterations, or compatible reflex changes.\n* Diagnosis or suspicion of cauda equina syndrome.\n* History of previous lumbar spine surgery.\n* Current vertebral fracture or recent history of lumbar fracture.\n* Spondylolisthesis grade II or higher.\n* Significant structural scoliosis or severe lumbar deformity that prevents treatment standardization.\n* Suspicion or evidence of a tumor, infection, spondylodiscitis, or axial inflammatory disease.\n* Severe clinically documented osteoporosis or history of vertebral fragility fracture.\n* Pregnancy or lactation.\n* Coagulation disorder, use of anticoagulants at therapeutic doses, or a hemorrhagic condition that increases procedure risk.\n* Previous epidural infiltration, facet block, radiofrequency, or other lumbar interventional procedure within a recent period defined by the protocol.\n* Current treatment with another physical rehabilitation modality or instrumental therapy directed at low back pain, if it cannot be suspended during the intervention period.\n* Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) that the patient cannot suspend according to the study indications.\n* Concomitant neurological, rheumatological, oncological, or musculoskeletal disease that significantly interferes with pain or disability evaluation.\n* Cognitive impairment, decompensated psychiatric disorder, or any condition that prevents understanding instructions, answering questionnaires, or completing follow-up.","80 Years",{"count":444,"type":21},60,[24],"The purpose of this clinical trial is to evaluate and compare the efficacy of two different dosing regimens of focal extracorporeal shock wave therapy (F-ESWT) in patients diagnosed with chronic mechanical low back pain. Participants will be randomly assigned to one of two experimental groups to receive different parameters of shock wave intervention. The main objective is to determine which dosing scheme provides a more significant reduction in pain intensity and a better recovery of lumbar function.",[68],[449,27,450,451],"Focal Extracorporeal Shock Wave Therapy","Dosing Regimens","Physical Medicine and Rehabilitation","2026-06-09",{"date":454,"type":44},"2026-06-12",{"date":426,"type":21},{"date":457,"type":21},"2028-01-30",{"name":459,"class":51},"Armando Tonatiuh Avila Garcia",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":466,"eligibilityCriteria":467,"healthyVolunteers":12,"sex":17,"minAge":332,"maxAge":91,"enrollmentInfo":468,"targetDuration":4,"studyType":22,"phases":470,"briefSummary":471,"conditions":472,"keywords":473,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":52},"100640141","seneca---smart-therapies-for-chronic-pain-100640141","NCT07628179","SENECA - Smart Therapies for Chronic Pain","Efficacy of Percutaneous Auricular Vagus Nerve Stimulation Within the Multimodal Pain Therapy (SENECA): A Randomized Controlled Pilot Study","SENECA","Inclusion Criteria:\n\n* Male or female aged between 30 and 65 years\n* Indication: chronic myofascial\u002Fmusculoskeletal back pain\n* normal function of spinal nerves\n* Intractable pain for more than 6 months\n* Patient on oral pharmacotherapy ≤ WHO II with no adequate response or intolerant\n* Average pain over the last 4 weeks according to the painDETECT subscale ≥ 4 and ≤ 9 at baseline\n* ODI 20-80 at baseline\n* Basic digital understanding to work with the patient pain app\n* Patient understands the therapy and procedures, agrees to its provisions, and gives written informed consent prior to any procedures\n\nExclusion Criteria:\n\n* Organic low back pain (trauma, fracture, tumor, infection, severe degenerative spine, documented high-grade spinal stenosis, rheumatologic conditions)\n* Indication for back surgery\n* Back surgery within the last 6 months\n* New analgesics 2 weeks before baseline (paracetamol, NSAIDs, Metamizol, etc.)\n* Opioid analgesic therapy \\> WHO II\n* New physical therapy modalities for back pain, also TENS, 2 weeks before baseline\n* History of vagus nerve stimulation or electrical auricular stimulation\n* History of vasovagal syncope\n* High BMI \\> 35 kg\u002Fm² (Obesity Class 2 or higher)\n* Hemophilia\n* Autonomic disorders\n* Advanced stage or poorly controlled diabetes mellitus type I or II\n* Poorly controlled high blood pressure\n* Major psychiatric comorbidity (HADS \\> 10 on each subscale at baseline)\n* Other serious clinically relevant co-morbidity\n* History of arrhythmia, bradycardia, other rhythm disorders or any other clinically significant cardiac anomalies\n* Infection, eczema, or psoriasis at application site (ear and neck)\n* Numbed and desensitized skin at the application site (ear and neck)\n* Chronic drug or alcohol abuse within the last 6 months\n* Pregnant or nursing female patients\n* Active implantable device\n* Open pension request\n* Currently participating in another clinical trial or participated over the last 3 months\n* Change in concomitant treatment or medication during the study",{"count":469,"type":21},44,[24],"This will be a randomized controlled prospective pilot study: The feasibility and usability of VIVO 2nd GEN therapy + Standard-of-Care (SoC) vs. Standard-of-Care alone will be evaluated.\n\nAt baseline, after informed consent and evaluation of inclusion and exclusion criteria, evaluation of pain on painDETECT, quality of life (EQ-5D-5L questionnaire), mental health (HADS questionnaire), and the effect of back pain on function and daily activities (ODI questionnaire) will be performed. After that, all patients will start their multimodal treatment plan.\n\nThe control group will only receive SoC multimodal therapy training (this includes specifically: physio group therapy, water therapy, strength training, Nordic walking, massages, thermos therapy, lectures and trainings, psychotherapy, local electrotherapy).\n\nThe treatment group will additionally receive pVNS as add-on therapy. Within this study the next generation device VIVO 2nd GEN will be used within a pVNS proofed indication.\n\nThe study documentation in both groups will be supported by a digital diary App (VIVO® Pal) and an online dashboard for physicians\u002Ftherapists (Therapy Management System - TMS), allowing for pseudonymized data entries and management.\n\nPatients will remain on treatment for 4 weeks. All patients will be evaluated using questionnaires (painDETECT, EQ-5D-5L, HADS, ODI) at baseline, weekly during treatment for 4 weeks, by end of treatment and at 4 weeks (optional 3 months and 6 months) follow-up (e.g., via telephone or the App, see below).",[68],[474,74,475,476,477],"auricular vagus nerve stimulation","neuromodulation","multimodal pain therapy","digital therapy management","2026-06-03",{"date":480,"type":44},"2026-06-04",{"date":482,"type":21},"2026-09-17",{"date":484,"type":21},"2027-04-30",{"name":486,"class":376},"Aurimod GmbH",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":61,"sex":17,"minAge":493,"maxAge":91,"enrollmentInfo":494,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":498,"conditions":499,"keywords":504,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":509,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":52},"100437952","early-phase-1-brain-mechanisms-supporting-cannabis-induced-pain-relief-100437952","NCT04982965","Brain Mechanisms Supporting Cannabis-induced Pain Relief","Inclusion Criteria:\n\n* Between 21-65 years old\n* Currently 30 days cannabis free\n* Lower back pain for three months or more\n* Are not taking opioids\n* If female and of a child bearing potential age, are not pregnant or nursing mothers\n* Do not have mental or neurological conditions inhibiting sensory\u002Fmotor functions\n* Do not have a lifetime history of dependence on cannabis\n* Do not have a lifetime history of DSM-IV schizophrenia, bipolar disorder, panic disorder, or psychosis\n* Prior THC-containing cannabis experience within the past two years\n* Agrees not to use cannabis outside of the study during participation in the study\n* Agrees not to use opioids or barbiturates during participation in the study\n* Agrees not to drive a motor vehicle within 4 hours following last use of inhaled cannabis during participation in the study\n\nExclusion Criteria:\n\n* Active pulmonary disease\n* Allergy or past adverse effects or negative past experiences from cannabis\n* Positive urine drug test for THC, barbiturates, opioids, oxycodone, or methadone\n* Any significant illness, including cardiovascular disease, diabetes, renal and liver disease.\n* Any current or history of an immunocompromising disease or condition (such as lupus, psoriasis, multiple sclerosis, etc.)\n* Any current or history of neurologic conditions, including Parkinson disease, dementia, cognitive impairment, history of seizure disorder, and history of traumatic brain injury\u002Fhead injury\n* Any current major psychiatric illness, such as bipolar disorder, major depression, psychosis, substance use disorder, or schizophrenia\n* Any current or history of suicidal ideation or attempt\n* Overt sensitivity to thermal stimulation\n* Resting blood pressure \\> 140\u002F90\n* Resting heart rate \\> 100 beats\u002Fminute\n* Prisoner\n* Institutionalized\n* Claustrophobia\n* MRI contraindications\n* Participation in any new (within 2 weeks prior or any time after enrollment) pain management procedures during the study period\n* Known history of vasovagal fainting, syncope, or severe adverse reactions associated with blood draws or needle procedures","21 Years",{"count":495,"type":21},100,[497],"EARLY_PHASE1","Chronic low back pain is a common and disabling condition that affects millions of people in the United States. Many people with chronic low back pain do not get enough relief from current treatments. Cannabis may help reduce pain, but researchers do not fully understand how it affects the brain in people with chronic pain. The purpose of this study is to examine how inhaled cannabis changes brain activity and reduces pain in people with chronic low back pain. Results from this study may help researchers better understand how cannabis works for pain and support the development of improved pain treatments.",[500,501,502,224,28,503,149],"Sciatica","Lumbar Radiculopathy","Lower Back Pain","Chronic Low Back and Leg Pain",[505,506,507,508],"Cannabis","Vaporized cannabis","THC","chronic low back pain","2026-05-30",{"date":478,"type":44},{"date":512,"type":44},"2021-05-07",{"date":514,"type":21},"2027-03-15",{"name":516,"class":51},"University of California, San Diego",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":4,"eligibilityCriteria":523,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":524,"targetDuration":4,"studyType":22,"phases":525,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":52},"100605372","chronic-low-back-pain-and-osteopathic-manipulation-treatment-100605372","NCT07161661","Chronic Low Back Pain and Osteopathic Manipulation Treatment","Feasibility of Implementing Manual Medicine in the Multimodal Management of Veterans and Service Members With Chronic Low Back Pain","Inclusion Criteria:\n\n* 18 years of age and older\n* Seeking care for LBP from a participating VA clinic\n* Able to follow study protocol\n* Willing to be randomized to Usual VA Care or Usual VA Care + OMT\n* Individuals with pain primarily in the LBP region lasting \\> 3 months and present on at least half the days during the past 6 months\n* Pain rating over the past 7 days equal to or greater than 3\u002F10 as indicated on the Numeric Rating Scale for Pain\n\nExclusion Criteria:\n\n* Signs of serious pathology as a cause of LBP\n* Underlying systemic or inflammatory conditions\n* Neurological diseases\n* Pregnancy\n* Previous back surgery or spinal fracture within the past year\n* Active workers' compensation or litigation for back pain\n* Any conditions impeding study protocol implementation or contraindication to OMT\n* No PM\\&R, OMT, chiropractic, or physical treatment where manual techniques are utilized within last 3mo",{"count":335,"type":21},[24],"The goal of this clinical trial is to learn if adding Osteopathic Manipulative Therapy (OMT) to the usual medical care provided at the VA (usual VA care) improves treatment outcomes in individuals with chronic low back pain (CLBP). OMT is a set of hands-on techniques a doctor uses to move a patient's muscles and joints which include stretching, gentle pressure, resistance and applying forces to specific areas of the body. This feasibility clinical trial aims to learn about the treatment effects (e.g., effect sizes) of adding OMT to the usual medical care provided at the VA (Usual VA Care) in individuals with LBP.",[68,27],[529,451,202,530],"Osteopathic manipulative treatment","Osteopathic manipulation","2026-05-21",{"date":533,"type":44},"2026-05-22",{"date":535,"type":44},"2026-03-02",{"date":537,"type":21},"2027-08-31",{"name":539,"class":540},"Edward Hines Jr. VA Hospital","FED",{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":4,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":91,"enrollmentInfo":548,"targetDuration":4,"studyType":22,"phases":550,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":52},"100607796","how-osteopathic-treatment-affects-the-leg-and-foot-in-people-with-low-back-pain-100607796","NCT07193212","How Osteopathic Treatment Affects the Leg and Foot in People With Low Back Pain","Osteopathic Manipulation Treatment Effect on the Leg and Foot Myofascial System in Adults With Chronic Low Back Pain - Pilot Study","Inclusion Criteria:\n\n* male and female subjects 18-65 years old\n* presence of chronic low back \\> 3 months duration or pain present \\> 50% of the time within the previous 12 months\n\nExclusion Criteria:\n\n* prior surgery of the thoracic, lumbar or sacral spine, pelvis\n* diagnosis lumbar radiculopathy or pinched nerve in the neck\n* diagnosis of foot condition that alters gait\n* diagnosis of connective tissue or muscle disorders\n* diagnosis of cancer\n* previous spinal cord injury inflammatory arthritis and fibromyalgia\n* pregnancy\n* tobacco use\n* known diabetes or prediabetes\n* allergy to ultrasound gel (propylene glycol)\n* history of manual therapy treatment within the past 2 weeks\n* injection for pain within the past 1 month\n* currently taking muscle relaxers",{"count":549,"type":21},20,[24],"This pilot study will examine whether osteopathic manipulative treatment (OMT) can improve both physical and psychological aspects of chronic low back pain by focusing on the interconnected myofascial system of the back, legs, and feet. Twenty adults with chronic low back pain will receive four OMT sessions over 5-7 weeks. Before and after treatment, the investigators will measure muscle stiffness with ultrasound, plantar pressure during walking with a pressure plate, and patient-reported outcomes on pain, disability, sleep quality, stress, anxiety, depression, pain catastrophizing, and pain self-efficacy using surveys. By linking these objective and subjective measures, the study aims to provide early evidence of how OMT may influence musculoskeletal function, daily activity, and overall well-being, helping to guide future larger studies on treatment strategies for low back pain",[68],[508,554,555],"myofascial systems","omt","2026-05-12",{"date":558,"type":44},"2026-05-14",{"date":560,"type":44},"2025-11-05",{"date":562,"type":21},"2026-12",{"name":564,"class":51},"Edward Via Virginia College of Osteopathic Medicine",{"id":566,"slug":567,"hasResults":12,"nctId":568,"briefTitle":569,"officialTitle":569,"acronym":570,"eligibilityCriteria":571,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":572,"targetDuration":4,"studyType":22,"phases":574,"briefSummary":575,"conditions":576,"keywords":580,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":52},"100532108","brief-pain-exposure-therapy-bpet-for-nociplastic-pain-100532108","NCT06208514","Brief Pain Exposure Therapy (BPET) For Nociplastic Pain","BPET","Inclusion Criteria:\n\n* Able to read, write and speak English\n* Internet access and audio-visual conferencing capability (e.g., Zoom meetings by phone or computer) in the home\n\nFibromyalgia participants must have:\n\n* Physician diagnosis of fibromyalgia\n* OR: meet 2016 American College of Rheumatology (ACR) Criteria for FM: Widespread pain index score is ≥ 7 and symptom severity scale score is ≥ 5, or widespread pain index score is 4 to 6 and symptom severity score is ≥ 9\n* OR: have pain self-reported in 4 out of 7 body regions in the General Sensory Sensitivity (GSS)-brief body map AND Opioid Use Disorder diagnosis by a physician.\n\nLupus participants must have:\n\n* Physician diagnosis of systemic lupus erythematosus\n* AND: Have pain self-reported in 4 out of 7 body regions in the GSS-brief body map\n* AND: No change in medications or steroid dose for one month prior to entry (to avoid oscillation of steroid dosing during the study due to active disease).\n\nChronic Low Back Pain participants must have:\n\n* Low Back Pain for at least half the days over the past 6 months\n* Over the past 7 days, an average pain intensity of at least 4 out of 10\n\nExclusion Criteria:\n\n* Indication of a co-occurring (non-fibromyalgia OR non-lupus) cause of chronic pain (e.g., inflammatory arthritis, other autoimmune disorders, spinal cord injury, cancer)\n* Currently receiving cognitive-behavioral therapy or other psychological therapies for pain\n* Open litigation regarding chronic pain in the past 1 year, as assessed in preliminary study screening.\n* Inability to provide informed consent and complete study procedures (e.g., indications of suspected major cognitive impairment via observations of study staff during consenting) that would preclude comprehension or participation in study protocols.\n* Pregnant or breastfeeding\n* Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.\n* Lupus group only: taking \\>10 mg prednisone (or equivalent steroid) dose per day as an indicator of ongoing disease activity (with no other strict exclusions based on medications)\n* Chronic Pelvic Pain group only: surgery for any chronic pelvic pain related condition in the past 6 months\n* Chronic low back pain only: scheduled back surgery; leg pain that is greater than your back pain",{"count":573,"type":21},125,[24],"This study is intended to test whether a brief Zoom-based behavioral treatment can help adults with fibromyalgia (FM), Lupus, chronic pelvic pain, and chronic low back pain learn effective strategies for reducing pain, disability and other problems that can come with fibromyalgia, Lupus, chronic pelvic pain, and chronic low back pain (such as depression or anxiety).",[577,578,579,68],"Fibromyalgia","Lupus Erythematosus, Systemic","Chronic Pelvic Pain",[581,582],"Pain exposure therapy","Telehealth-based behavioral intervention","2026-05-06",{"date":585,"type":44},"2026-05-11",{"date":587,"type":44},"2024-03-04",{"date":589,"type":21},"2027-07",{"name":591,"class":51},"University of Michigan",{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":17,"minAge":333,"maxAge":386,"enrollmentInfo":600,"targetDuration":4,"studyType":22,"phases":602,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":52},"100629500","exercise-based-strategies-for-chronic-back-pain-100629500","NCT07475481","Exercise-Based Strategies for Chronic Back Pain","Innovative Exercise-Based Strategies for Managing Chronic Back Pain: A Multisystem Health Approach","BACK-FIT","Inclusion Criteria:\n\n* Chronic low back pain lasting more than 12 weeks, with current low back pain at screening\u002Fbaseline.\n* Resting blood pressure below 139\u002F89 mmHg.\n* Health status allowing participation in moderate-intensity resistance training and aerobic activity.\n* Physically active, but not professional athletes.\n* Non-smoker.\n* Able and willing to provide written informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Absolute or relative contraindications to resistance training or other clinically relevant cardiovascular contraindications.\n* Coronary artery disease, heart rhythm disorders, acute myocarditis, Marfan syndrome, or other cardiovascular conditions judged unsafe by the study physician.\n* History of myocardial infarction, cerebrovascular disease, peripheral vascular disease, or grade II-IV hypertension.\n* Type 1 or type 2 diabetes mellitus.\n* Severe obesity (BMI \\>= 40.0 kg\u002Fm2).\n* Infectious disease at screening (for example, COVID-19 or influenza).\n* Current treatment for chronic low back pain from another healthcare provider.\n* Prior spine surgery or lower-limb surgery.\n* Structural spinal deformity such as spondylolisthesis or spondylolysis.\n* Spinal fracture, inflammatory spinal disorder, or neurological signs of nerve root compromise, including decreased tendon reflexes, sensory loss, or motor deficits.\n* Dizziness during exercise.\n* Use of medications other than analgesics and non-steroidal anti-inflammatory drugs, unless specifically approved by the study physician.",{"count":601,"type":21},120,[24],"This randomized, controlled, five-arm, parallel-group trial will evaluate the effects of 8 weeks of supervised resistance training and developmental position-based exercise, with or without real-time non-invasive intra-abdominal pressure biofeedback, in adults aged 40 to 60 years with chronic low back pain. The trial will compare supervised gym-based agonist-antagonist paired set resistance training with OHMTRACK, supervised gym-based resistance training without OHMTRACK, supervised physiotherapy-based developmental exercise with OHMTRACK, home-based developmental exercise with OHMTRACK, and an active control condition. Primary outcomes will assess changes in pain and physical function after the intervention. Secondary outcomes will include neuromuscular coordination, postural stabilization, cardiovascular, respiratory, metabolic, behavioral, feasibility, and follow-up outcomes.",[28],[508,606,607,608,609,610,611,612],"resistance training","exercise therapy","dynamic neuromuscular stabilization","developmental positions","intra-abdominal pressure","rehabilitation","postural stabilization","2026-03-11",{"date":615,"type":44},"2026-03-16",{"date":617,"type":21},"2027-07-01",{"date":619,"type":21},"2030-03-31",{"name":621,"class":51},"Charles University, Czech Republic",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":628,"maxAge":114,"enrollmentInfo":629,"targetDuration":4,"studyType":22,"phases":631,"briefSummary":632,"conditions":633,"keywords":634,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":645},"100616320","clinical-research-on-the-comparative-effectiveness-and-safety-of-jhg002-therapy-for-chronic-low-back-pain-a-multicenter-randomized-controlled-trial-100616320","NCT07304076","Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 19 to 69 years at the time of signing the informed consent.\n* Individuals who have experienced low back pain for ≥6 months, presenting with either continuous or intermittent symptoms.\n* Participants with a Numeric Rating Scale (NRS) score ≥ 5 for low back pain at screening.\n* Individuals who fully understand the clinical trial procedures and voluntarily agree to participate by providing written informed consent.\n\nExclusion Criteria:\n\n* Patients diagnosed with serious underlying conditions that may cause low back pain, such as spinal metastasis of malignancy, acute vertebral fracture, or spinal dislocation.\n* Patients with progressive neurological deficits or those presenting with severe neurological symptoms.\n* Patients whose pain originates from non-spinal soft tissue disorders, including tumors, fibromyalgia, rheumatoid arthritis, or gout.\n* Individuals with other chronic medical conditions that may interfere with treatment response or interpretation of study outcomes, such as stroke, myocardial infarction, chronic kidney disease, diabetic neuropathy, dementia, or epilepsy.\n* Individuals currently taking corticosteroids, immunosuppressants, psychiatric medications, or any other drugs that may influence study results.\\*\n* Patients for whom pharmacopuncture is inappropriate or unsafe, including those with bleeding disorders or those receiving anticoagulant therapy.\n* Individuals who have taken analgesic medications such as NSAIDs or received pharmacopuncture treatment within the past 1 week.\n* Women of childbearing potential who are unwilling to use medically acceptable contraception (e.g., surgical sterilization, intrauterine device, condom or diaphragm use, injectable or implantable contraceptives) throughout the study period.\n* Pregnant or breastfeeding women.\n* Individuals with a history of hypersensitivity or allergic reactions to Hominis placenta pharmacopuncture (JHG002).\n* Patients with uncontrolled diabetes mellitus (fasting blood glucose ≥ 180 mg\u002FdL).\n* Individuals whose AST (GOT) or ALT (GPT) levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Individuals whose serum creatinine levels are ≥ 2 times the upper limit of the normal range at the study site.\n* Patients suspected of having an underlying organic disease.\n* Patients with moderate systemic complications involving organs other than the heart, liver, or kidneys.\n* Patients with psychogenic disorders.\n* Individuals with an implanted cardiac pacemaker.\n* Patients with inflammation, infection, wounds, or other lesions at the planned pharmacopuncture sites that would prevent safe administration.\n* Patients within 3 months after lumbar spine surgery.\n* Individuals who have participated in another clinical trial within the past 1 month, or who plan to participate in another clinical trial-including follow-up periods-within 6 months from the screening date.\n* Any individual deemed unsuitable for participation in this study by the investigator.","19 Years",{"count":630,"type":21},96,[24],"A multicenter randomized controlled trial",[68],[508,635],"pharmacopuncture","2026-02-24",{"date":638,"type":44},"2026-02-25",{"date":640,"type":44},"2025-12-17",{"date":642,"type":21},"2029-11-28",{"name":644,"class":51},"Jaseng Medical Foundation",4,{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":652,"eligibilityCriteria":653,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":22,"phases":656,"briefSummary":657,"conditions":658,"keywords":659,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":377},"100610044","a-superiority-trial-of-radiofrequency-ablation-for-low-back-pain-100610044","NCT07222462","A Superiority Trial of Radiofrequency Ablation for Low Back Pain","ASTRAL: A Superiority Trial of Radiofrequency Ablation for Low Back Pain","ASTRAL","Inclusion Criteria:\n\n* Age ≥18 years\n* CLBP of duration ≥ 3 months. Low back pain is defined as occurring between the lower posterior margin of the rib cage and the horizontal gluteal fold.\n* Low back pain intensity numerical rating scale (NRS) ≥ 4 with one of the following prior to LRFA: 1) Current low back pain intensity, 2) Average pain over past 7 days, OR 3) Pain intensity without specification of recall period\n* Has had conservative treatments for CLBP (physical therapy, exercise therapy, spinal manipulation, massage, acupuncture, etc.)\n* Candidate for unilateral LRFA (L1-S1 joints; ≤3 levels); or bilateral LRFA (L1-S1 joints; ≤2 levels)\n* 'Positive responses' (≥80% improvement of CLBP pain intensity) to 2 sets of anesthetic-only MBBs (≤0.5cc of local anesthetic)\n* Able to read, speak, and understand English sufficient for informed consent purposes\n* Stated willingness to comply with all study processes and availability for the duration of the study, and provision of a signed and dated informed consent form\n\nExclusion Criteria:\n\n* CLBP attributed primarily to specific spine-related conditions (radiculopathy, lumbar spinal stenosis, spinal instability), 'red flag' conditions (infection \u002F malignancy \u002F fracture), and\u002For inflammatory arthritis (RA, SpA, etc.)\n* Prior LRFA\n* Prior lumbar facet joint (intra-articular or medial branch nerve) corticosteroid injections (past 6 months)\n* Surgery involving one or more of spinal levels where LRFA is to be performed, in the past 2 years\n* Lumbar fusion involving the spinal levels where LRFA is considered, at any time\n* Prior known severe lumbar central canal stenosis on MRI as defined by Lee (2011): obliteration of the cerebrospinal fluid (CSF), and marked compression of dural sac, and none of the cauda equina can be visually separated from each other. No new MRIs would be done specifically as part of the study processes.\n* Prior formal diagnosis of fibromyalgia by a rheumatologist (diagnosis by primary care physician or pain medicine specialist is not sufficient)\n* Unstable psychiatric or terminal medical conditions that would limit study participation and the likelihood of follow-up for 12 months post-randomization\n* Pregnancy, being a prisoner, or having a prior formal diagnosis of cognitive impairment by a neuropsychologist or neurologist, confirmed by health record documentation\n* Participant report of prior formal diagnosis of cognitive impairment by a neuropsychologist or neurologist can be obtained, but participant-reported cognitive impairment by a neuropsychologist or neurologist must be confirmed via health record documentation. No new evaluations for cognitive impairment would be done specifically as part of the study processes.\n* Contraindication to local anesthetic, corticosteroid, or any aspects of LRFA\n* Cannot reach MBB targets with 11.9cm needle\n* Major planned life events over the next 4 months that might interfere with study participation (e.g., major abdominal or chest surgery or extended vacation)",{"count":655,"type":21},300,[24],"The purpose of the ASTRAL Study is to evaluate the effectiveness of LRFA (Lumbar radiofrequency ablation) against a control procedure. The ASTRAL Study will enroll individuals with chronic low back pain (CLBP) and randomly assign them to one of three groups: lumbar radiofrequency ablation using conventional electrodes placed parallel to the medial branch nerves (LRFA-C), lumbar radiofrequency ablation using multi-tined electrodes placed perpendicular to the medial branch nerves (LRFA-M), or a simulated radiofrequency ablation procedure.",[68],[660,661],"lumbar radiofrequency ablation (LRFA)","corticosteroid injections","2026-02-05",{"date":664,"type":44},"2026-02-09",{"date":666,"type":44},"2026-02-04",{"date":668,"type":21},"2029-08",{"name":670,"class":51},"University of Washington",{"id":672,"slug":673,"hasResults":12,"nctId":674,"briefTitle":675,"officialTitle":676,"acronym":4,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":62,"enrollmentInfo":678,"targetDuration":4,"studyType":22,"phases":680,"briefSummary":681,"conditions":682,"keywords":685,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":696,"locationsCount":4},"100619534","connective-tissue-dry-needling-for-low-back-pain-related-to-local-posterior-superior-iliac-spine-pain-100619534","NCT07345871","Connective Tissue Dry Needling for Low Back Pain Related to Local Posterior Superior Iliac Spine Pain","Investigating the Effectiveness of Connective Tissue Dry Needling Technique on Patients With Low Back Pain Caused by Local Pain at Superior Posterior Iliac Spine: a Single-blind, Randomized Controlled Trial","Inclusion criteria:\n\n1. Adults aged 18 to 75 years.\n2. Diagnosed with chronic mechanical low back pain localized at the posterior superior iliac spine region.\n3. Presence of point tenderness reproducible by palpation at the posterior superior iliac spine area.\n4. Pain duration of at least two weeks, indicating the non-acute stage of low back pain.\n5. Negative results in at least three out of five sacroiliac pain provocation tests (Distraction, Compression, Thigh Thrust, Sacral Thrust, Gaenslen).\n6. Pain intensity ≥ 3 on the Numeric Rating Scale at baseline.\n7. Ability to communicate and cooperate with the research team during intervention and follow-up.\n8. Access to WhatsApp or equivalent communication application for follow-up pain reporting at the 3-month stage.\n\nNon-inclusion criteria:\n\n1. Presence of lumbar radicular pain or referred pain to the lower limbs.\n2. History of lumbar spine trauma within the previous three months.\n3. Fear or intolerance of needling procedures.\n4. Current use of anticoagulant medication.\n5. Known lymphatic disorders, immunosuppressive diseases, or neurological conditions such as epilepsy or seizure disorders.\n6. Pregnancy or suspected pregnancy.\n\nExclusion criteria:\n\n1. Voluntary withdrawal of consent at any time during the study.\n2. Inability to tolerate the intervention or adverse reaction during treatment sessions.\n3. Occurrence of serious adverse events or complications (e.g., infection, bleeding).\n4. Non-compliance with treatment protocol or missing more than two sessions.\n5. Any intercurrent illness or therapy that could interfere with the study outcomes or safety assessment",{"count":679,"type":21},42,[24],"This single-blind randomized controlled trial will aim to determine the effectiveness of a connective tissue dry needling (CTDN) technique, in reducing pain and improving function in individuals with chronic mechanical low back pain associated with pain and tenderness at the posterior superior iliac spine (PSIS). Forty participants with local PSIS-related low back pain will be recruited and randomly assigned into two groups using the block balanced randomization method. The treatment group will receive CTDN targeting connective tissue trigger points around the PSIS in addition to a sacroiliac joint stabilization exercise program, while the control group will perform the same exercise program alone under the supervision of a physiotherapist. The intervention protocol will span two weeks, during which participants will attend three treatment sessions per week, for a total of six sessions. The primary outcome measurement will use the Visual Analog Scale (VAS) to assess pain intensity. The study will measure secondary outcomes through lumbar range of motion (ROM) in flexion and extension and pressure pain threshold (PPT), and Roland-Morris Disability Questionnaire (RMDQ) functional disability and Short Form-36 (SF-36) health-related quality of life. The researchers will assess all outcomes at three time points: baseline and after the first session, and the sixth session, while VAS will receive an additional assessment at the 3-month follow-up. The findings of this study are expected to provide evidence supporting CTDN as a safe, effective, and cost-efficient treatment option for PSIS-related mechanical low back pain.",[68,683,684],"Sacroiliac Joint Dysfunction","Mechanical Low Back Pain",[684,683,686,687,688],"Connective Tissue Disorders","Dry Needling","Fascia \u002F Fascial Manipulation","2026-01-18",{"date":691,"type":44},"2026-01-21",{"date":693,"type":21},"2026-04-10",{"date":695,"type":21},"2026-09-01",{"name":697,"class":51},"University of Social Welfare and Rehabilitation Science"]